ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Long-Term Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Living Donor Renal Transplant Recipients

J. Leventhal1, J. Mathew1, J. Galvin2, L. Gallon1, D. Belshe1, K. Ravindra3, M. Horwitz3, J. Miller1, S. Ildstad4

1Northwestern, Chicago, IL, 2UIC, Chicago, IL, 3Duke, Durham, NC, 4U Louisville, Louisville, KY

Meeting: 2020 American Transplant Congress

Abstract number: 463

Keywords: Bone marrow transplantation, Kidney, Living donor, Tolerance

Session Information

Session Name: Tolerance

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 3:15pm-3:27pm

Location: Virtual

*Purpose: 37 pts have been transplanted since 2009 in a phase 2 protocol to induce tolerance in recipients of living donor renal allografts (KTx). The protocol is based upon tolerogenic CD8+/TCR-facilitating cells (FCRx) and nonmyeloablative conditioning.

*Methods: Pts were conditioned with fludarabine (30mg/m2/dose, days -5,-4,-3), cyclophosphamide (50mg/kg/dose, day-3 and+3), 200 cGy TBI (day-1) followed by KTx (day0). A G-CSF mobilized PBMC product was apheresed from the donor >2 weeks pre-KTx, processed to remove graft-versus-host disease (GVHD)-producing cells yet retain CD34 + cells and FC, and cryopreserved until administration day+1 post-KTx. All subjects have reached at least 3 years of FU (range 36 – 129 months) and are the focus of this analysis. Pts ranged in age from 18-65 yrs and were from 6/6 HLA matched related to 0/6 matched unrelated. 17 pts had unrelated and 20 had related donors. Two pts were re-transplants. MMF and tacrolimus based immunosuppression (IS) was weaned and d/c’d at 1 year if chimerism, normal renal fcn and normal KTx biopsy were noted.

*Results: 35 of 37 pts exhibited peripheral blood donor chimerism at one month post KTx. Durable chimerism allowing for full IS withdrawal developed in 26 pts (time off IS ranging from 24- 112 months); the majority (23/26) of these pts showed full (>95%) donor whole blood/T cell chimerism. All stable chimeric pts retained chimerism after removal of IS and remain rejection-free. Long term chimeric subjects off IS have shown no evidence of immune defect: they show robust lineage reconstitution, and they can be safely/effectively vaccinated. Transiently chimeric subjects resumed endogenous hematopoiesis and were maintained on low-dose IS with stable renal fcn. Late (> 4 yrs post-Tx) acute rejection occurred in two pts with transient chimerism who became noncompliant with IS. There have been two previously reported but no additional cases of GVHD. There have been three subject deaths; one in a pt with GVHD. one in a heavy (>100 pack year) smoker who developed advanced stage lung cancer 4.5 years after KTx, the third in a chimeric pt 3.5 years after KTx who developed pneumococcal sepsis – he was not compliant with recommended vaccinations. There have been two additional graft losses in our trial, both previously reported and related to infections. Overall pt survival is 91.8% and death censored graft survival 94.1%. Tolerant FCRx pts off IS have significantly better renal function than comparable KTx on SOC IS. Treatment for hypertension and hyperlipidemia is more common in SOC than tolerant FCRx pts

*Conclusions: Durable chimerism and tolerance with a low (5.5%) incidence of GVHD has been achieved in mismatched related/unrelated recipients of living donor KTx. We conclude there are significant long term medical benefits to establishing tolerance in KTx recipients using the FCRx approach.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Leventhal J, Mathew J, Galvin J, Gallon L, Belshe D, Ravindra K, Horwitz M, Miller J, Ildstad S. Long-Term Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Living Donor Renal Transplant Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/long-term-follow-up-of-a-phase-2-clinical-trial-to-induce-tolerance-in-living-donor-renal-transplant-recipients-2/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences